Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes
Conditions
- Adult Acute Myeloid Leukemia in Remission
- Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
- Adult Acute Myeloid Leukemia With Del(5q)
- Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
- Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
- Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
- Chronic Myelomonocytic Leukemia
- de Novo Myelodysplastic Syndromes
- Previously Treated Myelodysplastic Syndromes
- Recurrent Adult Acute Myeloid Leukemia
- Refractory Anemia With Excess Blasts
- Refractory Anemia With Excess Blasts in Transformation
- Refractory Anemia With Ringed Sideroblasts
- Refractory Cytopenia With Multilineage Dysplasia
- Secondary Myelodysplastic Syndromes
- Untreated Adult Acute Myeloid Leukemia
Interventions
- RADIATION: iodine I 131 monoclonal antibody BC8
- RADIATION: total-body irradiation
- PROCEDURE: allogeneic hematopoietic stem cell transplantation
- PROCEDURE: peripheral blood stem cell transplantation
- DRUG: fludarabine phosphate
- DRUG: cyclosporine
- DRUG: mycophenolate mofetil
- OTHER: laboratory biomarker analysis
Sponsor
Fred Hutchinson Cancer Center
Collaborators